Immunotherapy for metastatic melanoma

J Cell Biochem. 2012 Mar;113(3):725-34. doi: 10.1002/jcb.23402.


Melanoma has traditionally been considered an immunogenic tumor. A number of approaches have been studied for enhancement of antitumor immunity. The first cytokine approved for the treatment of metastatic melanoma, interleukin-2, has resulted in prolonged responses in a small subset of patients, providing hope that immunotherapy might be useful for this disease. Ipilimumab, a monoclonal antibody to CTLA-4, was recently approved and a number of other promising investigational approaches are currently being pursued. This manuscript discusses more recent advances in the treatment of melanoma employing a variety of immune-enhancing approaches.

Publication types

  • Review

MeSH terms

  • Antibodies / therapeutic use
  • Cancer Vaccines / therapeutic use
  • Cytokines / therapeutic use
  • Humans
  • Immunotherapy*
  • Immunotherapy, Adoptive
  • Melanoma / drug therapy
  • Melanoma / pathology
  • Melanoma / therapy*
  • Neoplasm Metastasis


  • Antibodies
  • Cancer Vaccines
  • Cytokines